

# SAFETY OF SUNITINIB VERSUS PAZOPANIB IN METASTATIC RENAL CANCER IN A TERTIARY HOSPITAL

GRP-168

Pérez Moreno MA, Desongles Corrales T, Acosta García HL,  
Villalba Moreno AM, Cotrina Luque J, Alfaro Lara ER  
Pharmacy Department. Hospital Virgen del Rocío. Seville. Spain.



## BACKGROUND


Sunitinib and pazopanib are tyrosine kinase inhibitors used in the treatment of metastatic renal cancer. Pazopanib has been recently marketed, so the clinical experience is not as extensive as that of sunitinib.

## OBJECTIVES

- ✓ To evaluate the safety profile of pazopanib and sunitinib in patients with metastatic renal cancer treated in a tertiary hospital.
- ✓ To compare the incidence of adverse reactions between the two drugs.

## METHODS

Patients treated with sunitinib or pazopanib



Patients selection

Metastatic renal cancer




SUNITINIB	PAZOPANIB
Line of therapy	
Adverse events detected	
Severity of adverse events	
Dose adjustments	


## RESULTS

34 patients identified → 26 patients selected


### Number of patients/line of therapy




### Frecuency of adverse events



### Severity of adverse events



### Dose adjustments



## CONCLUSIONS

Pazopanib was better tolerated than sunitinib, with an acceptable adverse events profile and fewer dose adjustments

The severity of adverse events was lower in the case of pazopanib

## AUTHOR DISCLOSURES PANEL

Authors disclosures concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this presentation:

Maria Antonia Pérez: Nothing to disclose

Trinidad Desongles: Nothing to disclose

Héctor L. Acosta: Nothing to disclose

Angela M. Villalba: Nothing to disclose

Jesús Cotrina: Nothing to disclose

Eva R. Alfaro: Nothing to disclose